Auven Therapeutics’ most common sector for investment islife science (100%). The Firm’s most common investment types include venture (60%) and buyout (lbo, mbo, mbi) (20%). In total, Auven Therapeutics has invested in 2 US states and 3 different countries.
Sign-up to view Auven Therapeutics’ full profile and discover more small private equity firm investors just like it.
6501 Redhook Plaza, Suite 201,
St. Thomas,
00802
Virgin Islands (U.S.)
(340) 779-6908
www.auventx.com
info@auventx.com
| Status | Dates | Company | Description | |
|---|---|---|---|---|
| Investment | Exit | |||
| Current | 2013-10-01 | - |
ADC Products
Life Science Switzerland |
ADC Products was formed in October, 2013 in conjunction with the sale of Spirogen Sarl to AstraZeneca. ADC-PS is the holding company that was created to hold all the Spirogen assets that were excluded from the sale of Spirogen Sarl to AstraZeneca, including milestone and royaly interests in PBD-based ADC’s in development under pre-existing licenses at the time of the sale of Spirogen Sarl. |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
